Melinta Therapeutics (MLNTQ) 10-Q 29 Oct 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Oct. 23, 2013
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	30-Sep-13
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3
Entity Registrant Name	CEMPRA, INC.
Entity Central Index Key	1461993
Current Fiscal Year End Date	-19
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		33,192,972

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current assets
Cash and equivalents	$110,403,348	$70,108,754
Receivables	974,778
Prepaid expenses	324,725	264,981
Total current assets	111,702,851	70,373,735
Furniture, fixtures and equipment, net	72,359	43,217
Deposits	322,298	321,394
Total assets	112,097,508	70,738,346
Current liabilities
Accounts payable	3,888,586	2,171,633
Accrued expenses	422,795	341,918
Accrued payroll and benefits	714,953	604,548
Deferred revenue	22,848
Warrant liability	821,138
Current portion of long-term debt	1,085,361	2,226,610
Total current liabilities	6,955,681	5,344,709
Deferred revenue	5,641,740
Long-term debt	13,435,309	7,623,285
Total liabilities	26,032,730	12,967,994
Commitments and contingencies
Shareholder's Equity
Common stock; $.001par value; 80,000,000 shares authorized; 24,903,774 and 33,186,656 issued and outstanding at December 31, 2012 and September 30, 2013	33,187	24,904
Additional paid-in capital	235,462,570	178,970,975
Deficit accumulated during the development stage	-149,430,979	-121,225,527
Total shareholders' equity	86,064,778	57,770,352
Total liabilities and shareholders' equity	$112,097,508	$70,738,346

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Statement Of Financial Position [Abstract]
Common shares, par value	$0.00	$0.00
Common shares authorized	80,000,000	80,000,000
Common shares issued	33,186,656	24,903,774
Common shares, shares outstanding	33,186,656	24,903,774

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended		94 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Revenue
Contract research	$1,172,268		$1,404,608		$1,404,608
License			4,335,412		4,335,412
Total revenue	1,172,268		5,740,020		5,740,020
Operating expenses
Research and development	11,919,394	3,156,011	25,617,340	12,456,062	109,344,900
General and administrative	2,167,234	1,494,824	6,895,937	4,244,278	28,458,397
Total operating expenses	14,086,628	4,650,835	32,513,277	16,700,340	137,803,297
Loss from operations	-12,914,360	-4,650,835	-26,773,257	-16,700,340	-132,063,277
Other income (expense)
Interest income	3,152	675	16,419	106,589	1,489,529
Interest expense	-736,288	-330,955	-1,448,614	-1,065,049	-7,087,936
Other income					488,958
Other income (expense), net	-733,136	-330,280	-1,432,195	-958,460	-5,109,449
Net loss and comprehensive loss	-13,647,496	-4,981,115	-28,205,452	-17,658,800	-137,172,726
Accretion of redeemable convertible preferred shares				-313,588	-14,002,842
Net loss attributable to common shareholders	($13,647,496)	($4,981,115)	($28,205,452)	($17,972,388)	($151,175,568)
Basic and diluted net loss attributable to common shareholders per share	($0.41)	($0.24)	($1)	($0.97)
Basic and diluted weighted average shares outstanding	33,184,322	21,038,008	28,187,011	18,450,507

Consolidated_Statements_of_Red

Consolidated Statements of Redeemable Preferred Shares and Shareholders' Equity (Deficit) (USD $)	Total	Series A Preferred Shares [Member]	Series B Preferred Shares [Member]	Series C Preferred Shares [Member]	Common Shares [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Deficit During the Development Stage [Member]
	USD ($)	USD ($)	USD ($)	USD ($)		USD ($)	USD ($)	USD ($)
Beginning balance at Nov. 18, 2005
Beginning balance, shares at Nov. 18, 2005
Net loss	-26,463							-26,463
Ending balance at Dec. 31, 2005	-26,463							-26,463
Ending balance, shares at Dec. 31, 2005
Beginning balance at Nov. 18, 2005
Beginning balance, shares at Nov. 18, 2005
Series C Warrant	-5,174,381
Beneficial conversion costs of Series B preferred shares			104,077
Reclassification of warrant liability to additional paid-in capital	1,033,647
Reclassification of additional paid-in capital to warrant liability	-241,587
Net loss	-137,172,726
Ending balance at Sep. 30, 2013	86,064,778
Ending balance, shares at Sep. 30, 2013
Beginning balance at Dec. 31, 2005	-26,463							-26,463
Beginning balance, shares at Dec. 31, 2005
Issuance of common shares to founders	171						171
Issuance of common shares to founders, shares					179,825
Issuance of preferred shares, net of share issuance costs		7,346,745
Issuance of common shares for service	14,583						14,583
Issuance of preferred shares, net of issuance costs, shares		789,191
Issuance of common shares for service, shares					30,702
Issuance of common shares for license agreement	91,362						91,362
Issuance of common shares for license agreement, shares					64,311
Issuance of preferred shares, net of share issuance costs		7,346,745
Issuance of preferred shares, net of issuance costs, shares		789,191
Accretion of redeemable convertible preferred shares	-232,782	232,782					-122,443	-110,339
Share-based compensation	16,327						16,327
Net loss	-2,228,948							-2,228,948
Ending balance at Dec. 31, 2006	-2,365,750	7,579,527						-2,365,750
Ending balance, shares at Dec. 31, 2006		789,191			274,838
Issuance of common shares upon exercise of options	5,250						5,250
Issuance of common shares upon exercise of options, shares					8,947
Issuance of preferred shares, net of share issuance costs		14,779,563	9,956,318
Issuance of preferred shares, net of issuance costs, shares		1,557,895	809,717
Conversion of Series A preferred shares to common shares upon financing participation default	523,644	-523,644					523,644
Conversion of Series A preferred shares to common shares upon financing participation default, shares		-55,120			55,120
Issuance of common shares to CEO	124,950						124,950
Issuance of common shares to CEO, shares					77,368
Issuance of common shares for license agreement	99,055						99,055
Issuance of common shares for license agreement, shares					61,335
Issuance of preferred shares, net of share issuance costs		14,779,563	9,956,318
Issuance of preferred shares, net of issuance costs, shares		1,557,895	809,717
Accretion of redeemable convertible preferred shares	-1,626,057	1,526,057	100,000				-808,919	-817,138
Share-based compensation	56,020						56,020
Net loss	-8,075,240							-8,075,240
Ending balance at Dec. 31, 2007	-11,258,128	23,361,503	10,056,318					-11,258,128
Ending balance, shares at Dec. 31, 2007		2,291,966	809,717		477,608
Issuance of common shares upon exercise of options	13,113						13,113
Issuance of common shares upon exercise of options, shares					13,469
Accretion of redeemable convertible preferred shares	-2,537,660	1,731,269	806,390				-106,124	-2,431,536
Share-based compensation	93,011						93,011
Net loss	-14,902,317							-14,902,317
Ending balance at Dec. 31, 2008	-28,591,981	25,092,772	10,862,708					-28,591,981
Ending balance, shares at Dec. 31, 2008		2,291,966	809,717		491,077
Issuance of preferred shares, net of share issuance costs				25,248,268
Issuance of preferred shares, net of issuance costs, shares				2,488,675
Series C Warrant				-5,174,381
Issuance of preferred shares, net of share issuance costs				25,248,268
Issuance of preferred shares, net of issuance costs, shares				2,488,675
Accretion of redeemable convertible preferred shares	-2,291,433	667,997	301,946	1,321,490			-123,404	-2,168,029
Beneficial conversion costs of Series B preferred shares	-73,995		73,995					-73,995
Share-based compensation	123,404						123,404
Net loss	-18,611,814							-18,611,814
Ending balance at Dec. 31, 2009	-49,445,819	25,760,769	11,238,649	21,395,377				-49,445,819
Ending balance, shares at Dec. 31, 2009		2,291,966	809,717	2,488,675	491,077
Issuance of common shares upon exercise of options	8,250						8,250
Issuance of common shares upon exercise of options, shares					3,947
Issuance of preferred shares, net of share issuance costs				20,490,721
Issuance of preferred shares, net of issuance costs, shares				2,000,700
Series C Warrant				8,597,116
Issuance of preferred shares, net of share issuance costs				20,490,721
Issuance of preferred shares, net of issuance costs, shares				2,000,700
Accretion of redeemable convertible preferred shares	-3,238,263	24,464	6,390	3,207,407			-174,061	-3,064,202
Beneficial conversion costs of Series B preferred shares	-30,082		30,082					-30,082
Share-based compensation	165,811						165,811
Net loss	-19,674,924							-19,674,924
Ending balance at Dec. 31, 2010	-72,215,027	25,785,233	11,275,121	53,690,621				-72,215,027
Ending balance, shares at Dec. 31, 2010		2,291,966	809,717	4,489,375	495,024
Issuance of common shares upon exercise of options	69,932						69,932
Issuance of common shares upon exercise of options, shares					38,815
Accretion of redeemable convertible preferred shares	-3,763,061	24,464	6,391	3,732,206			-513,717	-3,249,344
Share-based compensation	443,785						443,785
Net loss	-21,220,779							-21,220,779
Ending balance at Dec. 31, 2011	-96,685,150	25,809,697	11,281,512	57,422,827				-96,685,150
Ending balance, shares at Dec. 31, 2011		2,291,966	809,717	4,489,375	533,839
Issuance of common shares upon exercise of options	34,508					10	34,498
Issuance of common shares upon exercise of options, shares						10,351
Issuance of common stock upon initial public offering, net of issuance costs of $4.7 million	53,194,341					9,660	53,184,681
Issuance of common stock upon initial public offering, net of issuance of costs of $4.7 million, shares						9,660,000
Issuance of common stock upon private placement, net of issuance costs of $1.7 million	23,511,963					3,865	23,508,098
Issuance of common stock upon private placement, net of issuance costs of $1.7 million, shares						3,864,461
Conversion of common shares to common stock						534	-534
Conversion of common shares to common stock, shares					-533,839	533,839
Accretion of redeemable convertible preferred shares	-313,588	2,038	533	311,017				-313,588
Conversion of redeemable convertible preferred shares to common stock upon initial public offering	94,827,624	-25,811,735	-11,282,045	-57,733,844		9,959	94,817,665
Conversion of redeemable convertible preferred shares to common stock upon initial public offering, shares		-2,291,966	-809,717	-4,489,375		9,958,502
Conversion of convertible notes payable to common stock upon initial public offering	4,724,534					876	4,723,658
Conversion of convertible notes payable to common stock upon initial public offering, shares						876,621
Reclassification of warrant liability to additional paid-in capital	1,033,647						1,033,647
Share-based compensation	1,669,262						1,669,262
Net loss	-24,226,789							-24,226,789
Ending balance at Dec. 31, 2012	57,770,352					24,904	178,970,975	-121,225,527
Ending balance, shares at Dec. 31, 2012						24,903,774
Issuance of common shares upon exercise of options, shares
Conversion of redeemable convertible preferred shares to common stock upon initial public offering, shares	9,958,502
Share-based compensation	2,480,137						2,480,137
Issuance of common stock upon exercise of warrants	53,664					9	53,655
Issuance of common stock upon exercise of warrants, shares						8,944
Issuance of common stock upon public offering, net of issuance cost of $3.7 million	54,207,664					8,274	54,199,390
Issuance of common stock upon public offering, net of issuance cost of $3.7 million, shares						8,273,938
Reclassification of additional paid-in capital to warrant liability	-241,587						-241,587
Net loss	-28,205,452							-28,205,452
Ending balance at Sep. 30, 2013	$86,064,778					$33,187	$235,462,570	($149,430,979)
Ending balance, shares at Sep. 30, 2013						33,186,656

Consolidated_Statements_of_Red1

Consolidated Statements of Redeemable Preferred Shares and Shareholders' Equity (Deficit) (Parenthetical) (USD $)	12 Months Ended					9 Months Ended	12 Months Ended
	Dec. 31, 2007	Dec. 31, 2006	Dec. 31, 2007	Dec. 31, 2010	Dec. 31, 2009	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2012
	Series A Preferred Shares [Member]	Series A Preferred Shares [Member]	Series B Preferred Shares [Member]	Series C Preferred Shares [Member]	Series C Preferred Shares [Member]	Common Stock [Member]	IPO [Member]	Private Placement [Member]
							Common Stock [Member]	Common Stock [Member]
Issuance cost	$20,435	$150,570	$43,682	$9,279	$251,733	$3,700,000	$4,700,000	$1,700,000
Issuance cost	$20,435	$150,570	$43,682	$9,279	$251,733	$3,700,000	$4,700,000	$1,700,000

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended		94 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Operating activities
Net loss	($28,205,452)	($17,658,800)	($137,172,726)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	21,546	41,880	263,389
Issuance of common shares for service			14,583
Issuance of common shares for license agreement			190,418
Share-based compensation	2,480,137	1,189,182	5,172,707
Change in fair value of warrant liabilities	118,407	-87,204	3,449,208
Amortization of debt issuance costs	432,291	267,949	1,182,254
Changes in operating assets and liabilities
Receivables	-974,778		-974,778
Prepaid expenses	-59,744	123,358	-324,725
Deposits	-904	-311,524	-322,298
Accounts payable	1,716,953	-1,654,242	3,888,584
Accrued expenses	80,877	-52,394	679,740
Accrued payroll and benefits	110,405	81,200	714,952
Deferred revenue	5,664,588		5,664,588
Net cash used in operating activities	-18,615,674	-18,060,595	-117,574,104
Investing activities
Purchases of furniture, fixtures and equipment	-50,688	-8,437	-335,747
Purchase of investments			-14,306,177
Proceeds from sale of investments			14,306,177
Net cash used in investing activities	-50,688	-8,437	-335,747
Financing activities
Proceeds from borrowing on convertible promissory notes			8,100,000
Proceeds from borrowing on long-term debt	5,238,327		15,238,327
Payments on long-term debt	-238,327		-238,327
Proceeds from exercise of stock options and warrants	53,664	34,508	184,887
Proceeds from issuance of common stock, net of underwriting discounts	54,407,814	54,777,800	132,697,576
Payment of offering costs	-200,150	-702,716	-2,259,307
Payment of debt issuance costs	-300,372		-607,270
Proceeds from issuance of redeemable convertible preferred shares			75,197,313
Net cash provided by financing activities	58,960,956	54,109,592	228,313,199
Net change in cash and equivalents	40,294,594	36,040,560	110,403,348
Cash and equivalents at beginning of the period	70,108,754	15,602,264
Cash and equivalents at end of the period	110,403,348	51,642,824	110,403,348
Supplemental cash flow information
Cash paid for interest	846,422	679,111	1,766,936
Non-cash investing and financing activities
Accretion of redeemable convertible preferred shares		313,588	14,002,845
Allocation of the Class C proceeds to the Class C Purchase Option			5,174,381
Allocation of the convertible note proceeds to warrant			852,485
Allocation of the long-term debt proceeds to warrant	461,144		734,238
Conversion of convertible notes payable and accrued interest into common stock			4,724,534
Conversion of redeemable convertible preferred shares into common stock			94,827,625
Reclassification of warrant liability to additional paid-in capital			1,033,647
Reclassification of additional paid-in capital to warrant liability	241,587		241,587
Series B Preferred Shares [Member]
Non-cash investing and financing activities
Beneficial conversion costs of Series B preferred shares			104,077
Series A Preferred Shares [Member]
Non-cash investing and financing activities
Notes payable converted into Series A redeemable convertible preferred shares			3,100,000
Series C Preferred Shares [Member]
Non-cash investing and financing activities
Conversion of the Class C Purchase Option			($8,597,116)

Description_of_Business

Description of Business	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]
Description of Business	1. Description of Business
	Cempra, Inc. (the “Company” or “Cempra”, previously known as Cempra Holdings, LLC) is the successor entity of Cempra Pharmaceuticals, Inc. which was incorporated on November 18, 2005 and commenced operations in January 2006. Cempra is located in Chapel Hill, North Carolina, and is a pharmaceutical company developing medicines to treat drug-resistant bacterial infections in the community and hospital.
	On February 2, 2012, Cempra Holdings, LLC converted from a Delaware limited liability company to a Delaware corporation and was renamed Cempra, Inc. As a result of the corporate conversion, the holders of both common and preferred shares of Cempra Holdings, LLC became holders of shares of common stock of Cempra, Inc. Holders of options to purchase common shares of Cempra Holdings, LLC became holders of options to purchase shares of common stock of Cempra, Inc. Holders of notes convertible into preferred shares of Cempra Holdings, LLC and associated warrants exercisable for preferred shares of Cempra Holdings, LLC became holders of shares of common stock and warrants to purchase shares of common stock of Cempra, Inc.
	The Company is in its development stage as defined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 915, Development Stage Entities. The Company’s activities since inception have consisted principally of acquiring product and technology rights, raising capital and performing research and development activities. Since inception, the Company has incurred significant losses from operations and expects losses to continue for the foreseeable future. The Company’s success depends primarily on the successful development and regulatory approval of its product candidates and its ability to obtain adequate financing. As of September 30, 2013, the Company has incurred losses since inception of $137.2 million. The Company expects to continue to incur losses and require additional financial resources to advance its products to either the commercial stage or liquidity events.
	There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate revenues from collaborative partners on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations and financial condition.

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]
Basis of Presentation	2. Basis of Presentation
	Principles of Consolidation and Basis of Presentation
	The accompanying consolidated financial statements include the accounts and results of operations of Cempra, Inc. and its wholly owned subsidiaries. The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany balances and transactions have been eliminated in consolidation.
	Unaudited Interim Financial Data
	The accompanying interim consolidated financial statements are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the accompanying notes for the year ended December 31, 2012 contained in the Company’s Annual Report on Form 10-K. The unaudited interim consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of September 30, 2013 and the results of operations and cash flows for the three months and nine months ended September 30, 2012 and 2013. The December 31, 2012 consolidated balance sheet included herein was derived from audited consolidated financial statements, but does not include all disclosures including notes required by GAAP for complete financial statements.
	Use of Estimates
	The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	Receivables
	Receivables consist of amounts billed and earned but unbilled under the Company’s contract with the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services (“BARDA”). Receivables under the BARDA contract are recorded as qualifying research activities are conducted and invoices from the Company’s vendors are received. Unbilled receivables are also recorded based upon work estimated to be complete for which the Company has not received vendor invoices. The Company carries its accounts receivable at cost less an allowance for doubtful accounts. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance based on its history of collections and write-offs and the current status of all receivables. The Company does not accrue interest on trade receivables. If accounts become uncollectible, they will be written off through a charge to the allowance for doubtful accounts. The Company has not recorded an allowance for doubtful accounts as management believes all receivables are fully collectible.
	Clinical Trial Accruals
	As part of the process of preparing financial statements, the Company is required to estimate its expenses resulting from its obligation under contracts with vendors and consultants and clinical site agreements in connection with conducting clinical trials. The Company’s objective is to reflect the appropriate clinical trial expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. The Company determines accrual estimates through discussion with applicable personnel and outside service providers as to the progress of trials, or the services completed. During the course of a clinical trial, the Company adjusts its rate of clinical trial expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known at that time. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low for any particular period. Through September 30, 2013, there had been no material adjustments to the Company’s prior period estimates of accrued expenses for clinical trials. The Company’s clinical trial accrual is dependent upon the timely and accurate reporting of contract research organizations and other third-party vendors.
	Revenue Recognition
	The Company’s revenue generally consists of research related revenue under federal contracts and licensing revenue related to non-refundable upfront fees, milestone payments and royalites earned under license agreements. Revenue is recognized when the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products and/or services has occurred; (3) the selling price is fixed or determinable; and (4) collectability is reasonably assured.
	For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has “stand-alone value” to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling prices of each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods and services are delivered, limited to the consideration that is not contingent upon future deliverables. When an arrangement is accounted for as a single unit of accounting, the Company determines the period over which the performance obligations will be performed and revenue recognized.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2013
Investments All Other Investments [Abstract]
Fair Value of Financial Instruments	3. Fair Value of Financial Instruments
	The carrying values of cash equivalents, receivables, prepaid expenses, and accounts payable at September 30, 2013 approximated their fair values due to the short-term nature of these items.
	The Company’s valuation of financial instruments is based on a three-tiered approach, which requires that fair value measurements be classified and disclosed in one of three tiers. These tiers are: Level 1, defined as quoted prices in active markets for identical assets or liabilities; Level 2, defined as valuations based on observable inputs other than those included in Level 1, such as quoted prices for similar assets and liabilities in active markets, or other inputs that are observable or can be corroborated by observable input data; and Level 3, defined as valuations based on unobservable inputs reflecting the Company’s own assumptions, consistent with reasonably available assumptions made by other market participants.
	At December 31, 2012 and September 30, 2013, these financial instruments and respective fair values have been classified as follows:
		Quoted Prices			Significant		Significant		Balance at
		in Active			Other		Unobservable		December 31,
		Markets for			Observable		Inputs		2012
		Identical Assets			Inputs		(Level 3)
		(Level 1)			(Level 2)
	Assets:
	Money Market Funds	$	67,783,021		$	—	$	—		67,783,021
	Total assets at fair value:	$	67,783,021		$	—	$	—	$	67,783,021
		Quoted Prices			Significant		Significant		Balance at
		in Active			Other		Unobservable		September 30,
		Markets for			Observable		Inputs		2013
		Identical Assets			Inputs		(Level 3)
		(Level 1)			(Level 2)
	Assets:
	Money Market Funds	$	106,661,559		$	—	$	—		106,661,559
	Total assets at fair value:	$	106,661,559		$	—	$	—	$	106,661,559
	Liabilities:
	Warrant liabilities	$	—		$	—	$	821,138		821,138
		$	—		$	—	$	821,138	$	821,138
	The change in the fair value measurement using significant unobservable inputs (Level 3) is summarized below:
	Balance at December 31, 2012	$	—
	Allocation of long-term debt proceeds to warrant (Unaudited)		461,144
	Reclassification of additional paid-in capital to warrant (Unaudited)		241,587
	Change in fair value recorded as interest income (Unaudited)		(14,355	)
	Change in fair value recorded as interest expense (Unaudited)		132,762
	Balance at September 30, 2013 (Unaudited)	$	821,138
	The December 2011 Note, which is classified as a level 2 liability (see Note 8) has a variable interest rate and, accordingly, its carrying value approximates its fair value. At September 30, 2013, the carrying value was $14.5 million. There were no transfers between levels of the fair value hierarchy in the three and nine months ended September 30, 2013.

Significant_Agreements_and_Con

Significant Agreements and Contracts	9 Months Ended
	Sep. 30, 2013
Text Block [Abstract]
Significant Agreements and Contracts	4. Significant Agreements and Contracts
	License Agreements
	Optimer Pharmaceuticals, Inc.
	In March 2006, the Company, through its wholly owned subsidiary, Cempra Pharmaceuticals, Inc., entered into a Collaborative Research and Development and License Agreement (“Optimer Agreement”) with Optimer Pharmaceuticals, Inc. (“Optimer”). Under the terms of the Optimer Agreement, the Company acquired exclusive rights to further develop and commercialize certain Optimer technology worldwide, excluding member nations of the Association of Southeast Asian Nations.
	In exchange for this license, during 2006 and 2007, the Company issued an aggregate of 125,646 common shares with a total fair value of $190,418 to Optimer. These issuances to Optimer were expensed as incurred in research and development expense.
	In July 2010, the Company paid a $500,000 milestone payment to Optimer after the successful completion of its first solithromycin Phase 1 program. In July 2012, the Company paid a $1,000,000 milestone after the successful completion of its first solithromycin Phase 2 program. Both milestones were expensed as incurred in research and development expense. Under the terms of the Optimer Agreement, the Company will owe Optimer additional payments, contingent upon the achievement of various development, regulatory and commercialization milestone events. The aggregate amount of such milestone payments the Company may need to pay is based in part on the number of products developed under the agreement and would total $27,500,000 (including payments made to date) if four products are developed through FDA approval. The Company will also pay tiered mid-single-digit royalties based on the amount of annual net sales of its approved products.
	The Scripps Research Institute
	In June 2012, the Company entered into a license agreement with The Scripps Research Institute (“TSRI”), whereby TSRI licensed to the Company rights, with rights of sublicense, to make, use, sell, and import products for human or animal therapeutic use that use or incorporate one or more macrolides as an active pharmaceutical ingredient and is covered by certain patent rights owned by TSRI claiming technology related to copper-catalysed ligation of azides and acetylenes. The rights licensed to the Company are exclusive as to the People’s Republic of China (excluding Hong Kong), South Korea and Australia, and are non-exclusive in all other countries worldwide, except the member-nations of the Association of Southeast Asian Nations, which are not included in the territory of the license. Under the terms of the agreement with TSRI, the Company paid a one-time only, non-refundable license issue fee in the amount of $350,000 which was charged to research and development expense in the second quarter of 2012.
	The Company is also obligated to pay annual maintenance fees to TSRI in the amount of (i) $50,000 each year for the first three years (beginning on the first anniversary of the agreement), and (ii) $85,000 each year thereafter (beginning on the fourth anniversary of the agreement). Each calendar year’s annual maintenance fees will be credited against sales royalties due under the agreement for such calendar year. Under the terms of the agreement, the Company must pay TSRI low single-digit percentage royalties on the net sales of the products covered by the TSRI patents for the life of the TSRI patents, a low single-digit percentage of non-royalty sublicensing revenue received with respect to countries in the nonexclusive territory and a mid-single-digit percentage of sublicensing revenue received with respect to countries in the exclusive territory, with the sublicensing revenue royalty in the exclusive territory and the sales royalties subject to certain reductions under certain circumstances. TSRI is eligible to receive milestone payments of up to $1.1 million with respect to regulatory approval in the exclusive territory and first commercial sale, in each of the exclusive territory and nonexclusive territory, of the first licensed product to achieve those milestones that is based upon each macrolide covered by the licensed patents. Each milestone is payable once per each macrolide. Each milestone payment made to TSRI with respect to a particular milestone will be creditable against any payment due to TSRI with respect to any sublicense revenues received in connection with the achievement of such milestone. Pursuant to the terms of the Optimer Agreement, any payments made to TSRI under this license for territories subject to the Optimer Agreement can be deducted from any sales-based royalty payments due under the Optimer Agreement up to a certain percentage reduction of the royalties due to Optimer.
	Under the terms of the agreement, the Company is also required to pay additional fees on royalties, sublicensing and milestone payments if the Company, an affiliate with TSRI, or a sublicensee challenges the validity or enforceability of any of the patents licensed under the agreement. Such increased payments would be required until all patent claims subject to challenge are invalidated in the particular country where such challenge was mounted.
	Biomedical Advanced Research and Development Authority
	In May 2013, the Company entered into an agreement with BARDA, for the evaluation and development of the Company’s lead product candidate solithromycin for the treatment of bacterial infections in pediatric populations and infections caused by bioterror threat pathogens, specifically anthrax and tularemia.
	The agreement is a cost plus fixed fee development contract, with a base performance segment valued at approximately $17.7 million, and four option work segments that BARDA may request at its sole discretion pursuant to the agreement. If all four option segments are requested, the cumulative value of the agreement would be approximately $58 million. Three of the options are cost plus fixed fee arrangements and one option is a cost sharing arrangement for which the Company would be responsible for a designated portion of the costs associated with that work segment. The estimated period of performance for the base performance segment is May 24, 2013 through May 23, 2015. If all option segments are requested, this estimated period of performance would be extended until approximately May 23, 2018.
	Under the agreement, the Company is reimbursed and recognizes revenue as allowable costs are incurred plus a portion of the fixed-fee earned. The Company considers fixed-fees under cost reimbursable agreements to be earned in proportion to the allowable costs incurred in performance of the work as compared to total estimated agreement costs, with such costs incurred representing a reasonable measurement of the proportional performance of the work completed. For the three-month and nine-month periods ended September 30, 2013, the Company recognized $1.2 million and $1.4 million, respectively in revenue under this agreement.
	The agreement provides the U.S. government the ability to terminate the agreement for convenience or to terminate for default if the Company fails to meet its obligations as set forth in the statement of work. The Company believes that if the government were to terminate the agreement for convenience, the costs incurred through the effective date of such termination and any settlement costs resulting from such termination would be allowable costs.
	Toyama Chemical Co., Ltd.
	In May 2013, Cempra Pharmaceuticals, Inc., the Company’s wholly owned subsidiary, entered into a license agreement with Toyama Chemical Co., Ltd. (“Toyama”), whereby the Company licensed to Toyama the exclusive right, with the right to sublicense, to make, use and sell any product in Japan that incorporates solithromycin, the Company’s lead compound, as its sole active pharmaceutical ingredient, or API, for human therapeutic uses, other than for ophthalmic indications or any condition, disease or affliction of the ophthalmic tissues. Toyama also has a nonexclusive license in Japan and certain other countries, with the right to sublicense, to manufacture or have manufactured API for solithromycin for use in manufacturing such products, subject to limitations and obligations of the concurrently executed supply agreement discussed below. Toyama granted the Company certain rights to intellectual property generated by Toyama under the license agreement with respect to solithromycin or licensed products for use with such products outside Japan or with other solithromycin-based products inside or outside Japan.
	Following execution of the agreement, the Company received a $10.0 million upfront payment from Toyama. Toyama is also obligated to pay the Company up to an aggregate of $60.0 million in milestone payments, depending on the achievement of various regulatory, patent, development and commercial milestones. Under the terms of the license agreement, Toyama must also pay the Company a royalty equal to a low-to-high first double decimal digit percentage of net sales, subject to downward adjustment in certain circumstances.
	As part of the license agreement, Toyama and the Company also entered into a supply agreement, whereby the Company will be the exclusive supplier (with certain limitations) to Toyama and its sublicensees of API for solithromycin for use in licensed products in Japan, as well as the exclusive supplier to Toyama and its sublicensees of finished forms of solithromycin to be used in Phase 1 and Phase 2 clinical trials in Japan. Pursuant to the supply agreement, which is an exhibit to the license agreement, Toyama will pay the Company for such clinical supply of finished product and all supplies of API for solithromycin for any purpose, other than the manufacture of products for commercial sale in Japan, at prices equal to the Company’s cost. All API for solithromycin supplied by the Company to Toyama for use in the manufacture of finished product for commercial sale in Japan will be ordered from the Company at prices determined by the Company’s manufacturing costs, and which may, depending on such costs, equal, exceed, or be less than such costs. Either party may terminate the supply agreement for uncured material breach or insolvency of the other party, with Toyama’s right to terminate for the Company’s breach subject to certain further conditions in the case of the Company’s failure to supply API for solithromycin or clinical supply, but otherwise the supply agreement will continue until the expiration or termination of the license agreement.
	The Company has determined that there are six deliverables under this agreement including (1) the license to develop and commercialize solithromycin in Japan, (2) the obligation of the Company to conduct Phase 3 studies and obtain regulatory approval in the United States and one other territory, (3) participation in a Joint Development Committee, or JDC, (4) participation in a Joint Commercialization Committee, or JCC, (5) the right to use the Company’s trademark, and (6) a supply agreement. The amounts received under the license agreement have been allocated to the deliverables based on their relative fair values and will be recognized into income when the revenue recognition criteria have been achieved. As of September 30, 2013, the license is the only unit of accounting that has been delivered. The Company has recognized $4.3 million in revenue associated with the delivery of the license. The Company has recorded $5.7 million as deferred revenue at September 30, 2013 which will be recorded as revenue when the revenue recognition criteria of each deliverable have been met.
	Milestone payments are recognized when earned, provided that (i) the milestone event is substantive; (ii) there is no ongoing performance obligation related to the achievement of the milestone earned; and (iii) it would result in additional payments. Milestone payments are considered substantive if all of the following conditions are met: the milestone payment is non-refundable; achievement of the milestone was not reasonably assured at the inception of the arrangement; substantive effort is involved to achieve the milestone; and the amount of the milestone appears reasonable in relation to the effort expended, the other milestones in the arrangement, and the related risk associated with the achievement of the milestone. Contingent-based payments the Company may receive under a license agreement will be recognized when received.
	Royalties are recorded as earned in accordance with the contract terms when third party sales can be reliably measured and collectability is reasonably assured.

Receivables

Receivables	9 Months Ended
	Sep. 30, 2013
Receivables [Abstract]
Receivables	5. Receivables
	Receivables consist of billed and unbilled amounts that have been earned under the Company’s licensing agreements or its contract with BARDA. At September 30, 2013, the Company had $974,778 of earned but unbilled receivables under the BARDA agreement.

Furniture_Fixtures_and_Equipme

Furniture, Fixtures and Equipment	9 Months Ended
	Sep. 30, 2013
Property Plant And Equipment [Abstract]
Furniture, Fixtures and Equipment	6. Furniture, Fixtures and Equipment
	Furniture, fixtures and equipment consist of the following as of:
		Useful Life		December 31,		September 30,
		(years)		2012		2013
						(Unaudited)
	Computer equipment		2	$	191,889	$	215,104
	Software		2		46,594		39,952
	Furniture		5		38,792		38,792
	Leasehold improvements		3		4,809		13,680
	Total furniture, fixtures and equipment				282,084		307,528
	Less accumulated depreciation				238,867		235,169
	Furniture, fixtures and equipment, net			$	43,217	$	72,359
	During the three-month period ended September 30, 2012 and 2013, the Company recorded $5,452 and $7,641 in depreciation expense, respectively. During the nine-month period ended September 30, 2012 and 2013, the Company recorded $41,879 and $21,546 in depreciation expense, respectively. Depreciation expense for the cumulative period from inception through September 30, 2013 was $263,389.

Accrued_Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2013
Payables And Accruals [Abstract]
Accrued Expenses	7. Accrued Expenses
	Accrued expenses are comprised of the following as of:
		December 31,		September 30,
		2012		2013
				(Unaudited)
	Accrued professional fees	$	207,362	$	242,977
	Other accrued fees		30,817		45,693
	Accrued interest		82,236		119,375
	Deferred rent		21,503		14,750
	Total accrued expenses	$	341,918	$	422,795

LongTerm_Debt

Long-Term Debt	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]
Long-Term Debt	8. Long-term Debt
	In December 2011, the Company entered into a $20,000,000 loan and security agreement (the “December 2011 Note”) with Hercules Technology Growth Capital, Inc. (“Hercules”) and borrowed $10,000,000 upon closing. The principal amount outstanding under the $10,000,000 borrowing bears interest at the greater of (i) 9.55%, or (ii) the sum of 9.55% plus the prime lending rate, as published by the Wall Street Journal, minus 3.25% per annum. The terms of the December 2011 Note agreement provided that the Company could, at any time prior to October 1, 2012, request another borrowing in the aggregate amount of $10,000,000. The Company elected not to request the additional borrowing and let the option expire on September 30, 2012. In May 2013, the Company amended its December 2011 Note, increasing the intial loan amount to $15,000,000, receiving an additional $5,238,327 upon closing. The Company also extended the date by which it could request the additional $10,000,000 to September 30, 2013. The Company elected not to request the additional borrowing and let the option expire on September 30, 2013. This amendment also provides for the Company to make interest only payments through June 2014. Principal and interest payments will start July 1, 2014 over a 36-month amortization period. The principal balance outstanding on the loan agreement and all accrued but unpaid interest thereunder will be due and payable on June 1, 2017. In addition, the Company is to pay Hercules the following fees:
		•	$400,000 on the earliest to occur of (i) December 1, 2015, (ii) the date that the Company prepays all of the outstanding advances and accrued interest, or (iii) the date that all of the advances and interest become due and payable.
		•	$495,245 on the earliest to occur of (i) June 1, 2017, (ii) the date that the Company prepays all of the outstanding advances and accrued interest, or (iii) the date that all of the advances and interest become due and payable.
	The Company granted Hercules a security interest in all of its assets, except intellectual property. The Company’s obligations to Hercules include restrictions on borrowing, asset transfers, placing liens or security interests on the Company’s assets including its intellectual property, mergers and acquisitions and distributions to stockholders.
	In connection with the initial closing of the December 2011 note, the Company entered into a warrant agreement with Hercules (the “First Hercules Warrant”), under which Hercules has the right to purchase 39,038 shares of the Company’s common stock. The exercise price of the First Hercules Warrant was initially $10.25 per share, subject to adjustment in the event of a merger, reclassification, subdivision or combination of shares or stock dividend and subject also to antidilution protection. In connection with the amendment to the loan agreement, the exercise price of the first Hercules Warrant was reduced to the lower of (a) $6.11, and (b) the effective price per share of the Company's common stock issued or issuable in any offering of the Company’s equity or equity-linked securities that occurs prior to June 1, 2014, provided that such offering is effected principally for equity or debt-financing purposes. The First Hercules Warrant expires on December 20, 2021. Proceeds equal to the fair value of the Hercules Warrant were recorded as a liability at the date of issuance and the borrowings under the December 2011 Note will be increased to equal the face amount of the borrowings plus interest through interest expense over the term of the loan using the effective interest method. Upon completion of the Company’s initial public offering (“IPO”), the warrant liability was reclassified to additional paid-in capital. Since the amendment to the warrant resulted in a variable exercise price, the fair value of the warrant as of the date of the amendment was reclassified from additional paid-in capital to a warrant liability.
	Additionally, in connection with the amendment of the December 2011 note, the Company entered into a warrant agreement with Hercules (the “Second Hercules Warrant”), under which Hercules has the right to purchase an aggregate number of shares of the Company’s common stock equal to the quotient derived by dividing $609,533 by the exercise price then in effect, which is defined as the lower of (a) $6.11, and (b) the effective price per share of the Company’s common stock issued or issuable in any offering of the Company’s equity or equity-linked securities that occurs prior to June 1, 2014, provided that such offering is effected principally for equity or debt-financing purposes. The exercise price is subject to adjustment in the event of a merger, reclassification, subdivision or combination of shares or stock dividend and subject also to antidilution protection. The Second Hercules Warrant expires on May 31, 2023. Proceeds equal to the fair value of the Second Hercules Warrant were recorded as a liability at the date of issuance and the borrowings under the December 2011 Note will be increased to equal the face amount of the borrowings plus interest through interest expense over the term of the loan using the effective interest method.

Shareholders_Equity_Deficit

Shareholders' Equity (Deficit)	9 Months Ended
	Sep. 30, 2013
Equity [Abstract]
Shareholders' Equity (Deficit)	9. Shareholders’ Equity (Deficit)
	Initial Public Offering
	During February 2012, the Company completed its IPO, issuing 9,660,000 shares of common stock, at a price of $6.00 per share, resulting in net proceeds to the Company of approximately $53.2 million after deducting underwriting discounts of $3.2 million and offering costs of $1.6 million.
	In connection with the IPO, all of the Company’s outstanding preferred shares, including accrued yield of $13.7 million, automatically converted into a total of 9,958,502 shares of its common stock and the preferred stock warrant liability was reclassified to additional paid-in capital upon the conversion of warrants to purchase preferred stock into warrants to purchase common stock. In addition, the Company’s August 2011 Notes and related accrued interest converted into 876,621 shares of common stock.
	Private Placement
	During October 2012, the Company sold 3,864,461 shares of its common stock at $6.50 per share to certain institutional accredited investors in a private placement financing, raising an aggregate of $25.1 million before sales agency fees and offering costs of approximately $1.7 million. In connection with this financing, the Company entered into a registration rights agreement, pursuant to which it registered the resale of the shares of common stock issued in the financing.
	Public Offering
	During June 2013, the Company completed a public offering issuing 8,273,938 shares of common stock, at a price of $7.00 per share, resulting in net proceeds to the Company of approximately $54.2 million after deducting underwriting discounts of $3.5 million and offering costs of $0.2 million.

Share_Option_Plans

Share Option Plans	9 Months Ended
	Sep. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share Option Plans	10. Share Option Plans
	The Company adopted the 2006 Stock Plan in January 2006 (“the 2006 Plan”). The 2006 Plan provided for the granting of incentive share options, nonqualified share options and restricted shares to Company employees, representatives and consultants. As of September 30, 2013, there were options for an aggregate of 702,185 shares issued and outstanding under the 2006 Plan.
	The Company’s board of directors adopted the 2011 Equity Incentive Plan in October 2011 (the “2011 Plan”), and authorized the issuance of up to 1,526,316 shares for future issuances under the 2011 Plan. During January 2013, the authorized shares under the 2011 Plan automatically increased by 105,263 shares. During May 2013, the Company’s shareholders approved an increase of 1,500,000 shares reserved under the 2011 Plan. As of September 30, 2013, there were 2,024,728 option shares available under the 2011 Plan.
	The 2011 Plan became effective upon the conversion of Cempra Holdings, LLC from a limited liability company to a corporation on February 2, 2012 and was adopted by the Company’s shareholders immediately thereafter. Upon effectiveness of the 2011 Plan, the Company eliminated the authorization for any unissued shares previously reserved under the Company’s 2006 Plan. The stock awards previously issued under the 2006 Plan remain in effect in accordance with the terms of the 2006 Plan.
	The following table summarizes the Company’s 2006 Plan and 2011 Plan activity:
			Number of			Weighted		Weighted		Aggregate
			Options			Average		Average		Intrinsic
						Exercise		Contractual		Value (1)
						Price		Term (in years)
	Outstanding—December 31, 2012			1,162,602		$	4.18
	Granted			698,473			6.73
	Exercised			—			—
	Forfeited			(54,539	)		7.62
	Expired			—			—
	Outstanding—September 30, 2013			1,806,536			5.07		7.83	$	11,622,016
	Exercisable—September 30, 2013			1,376,922			4.79		7.48	$	9,245,384
	Vested and expected to vest at September 30, 2013 (2)			1,763,647		$	5.04		7.8	$	11,384,658
	(1)	Intrinsic value is the excess of the fair value of the underlying common shares as of September 30, 2013 over the weighted-average exercise price.
	(2)	The number of stock options expected to vest takes into account an estimate of expected forfeitures.
	The following table summarizes certain information about all options outstanding as of September 30, 2013:
			Options Outstanding					Options Exercisable
	Exercise Price		Number of			Weighted		Number of		Weighted
			Options			Average		Options		Average
						Remaining				Remaining
						Contractual				Contractual
						Term (in years)				Term (in years)
	$0.48—$1.71			97,688			2.94		97,688		2.94
	$1.71—$2.94			604,497			6.35		526,148		6.22
	$5.40—$7.86			1,104,351			9.07		753,086		8.94
				1,806,536					1,376,922
	During the three-month period ended September 30, 2012 and 2013, the Company recorded $518,572 and $861,392 in share-based compensation expense, respectively. During the nine-month period ended September 30, 2012 and 2013, the Company recorded $1,189,182 and $2,480,137 in share-based compensation expense, respectively. Since inception, the Company has recognized $5,172,708 in share-based compensation expense. As of September 30, 2013, approximately $1,741,000 of total unrecognized compensation cost related to unvested share options is expected to be recognized over a weighted-average period of 1.8 years.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]
Income Taxes	11. Income Taxes
	The Company estimates an annual effective tax rate of 0% for the year ending December 31, 2013 as the Company incurred losses for the nine-month period ended September 30, 2013 and is forecasting additional losses through the fourth quarter, resulting in an estimated net loss for both financial statement and tax purposes for the year ending December 31, 2013. Therefore, no federal or state income taxes are expected and none have been recorded at this time. Income taxes have been accounted for using the liability method in accordance with FASB ASC 740.
	Due to the Company’s history of losses since inception, there is not enough evidence at this time to support that the Company will generate future income of a sufficient amount and nature to utilize the benefits of its net deferred tax assets. Accordingly, the deferred tax assets have been reduced by a valuation allowance, since it has been determined that it is more likely than not that all of the deferred tax assets will not be realized.

Net_Loss_Per_Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]
Net Loss Per Share	12. Net Loss Per Share
	Basic and diluted net loss per common share was determined by dividing net loss attributable to common shareholders by the weighted average common shares outstanding during the period. The Company’s potentially dilutive shares, which include redeemable convertible preferred shares, convertible debt, warrants and common share options, have not been included in the computation of diluted net loss per share for all periods as the result would be antidilutive.
	The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding, as they would be antidilutive:
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2012		2013		2012		2013
		(Unaudited)				(Unaudited)
	Redeemable convertible preferred shares		—		—		923,847		—
	Convertible debt		—		—		59,685		—
	Warrants outstanding		247,370		340,519		236,217		289,723
	Stock options outstanding		1,157,545		1,815,830		1,011,738		1,699,525
			1,404,915		2,156,349		2,231,487		1,989,248

Basis_of_Presentation_Policies

Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation
	The accompanying consolidated financial statements include the accounts and results of operations of Cempra, Inc. and its wholly owned subsidiaries. The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany balances and transactions have been eliminated in consolidation.
Unaudited Interim Financial Data	Unaudited Interim Financial Data
	The accompanying interim consolidated financial statements are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the accompanying notes for the year ended December 31, 2012 contained in the Company’s Annual Report on Form 10-K. The unaudited interim consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of September 30, 2013 and the results of operations and cash flows for the three months and nine months ended September 30, 2012 and 2013. The December 31, 2012 consolidated balance sheet included herein was derived from audited consolidated financial statements, but does not include all disclosures including notes required by GAAP for complete financial statements.
Use of Estimates	Use of Estimates
	The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Receivables	Receivables
	Receivables consist of amounts billed and earned but unbilled under the Company’s contract with the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services (“BARDA”). Receivables under the BARDA contract are recorded as qualifying research activities are conducted and invoices from the Company’s vendors are received. Unbilled receivables are also recorded based upon work estimated to be complete for which the Company has not received vendor invoices. The Company carries its accounts receivable at cost less an allowance for doubtful accounts. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance based on its history of collections and write-offs and the current status of all receivables. The Company does not accrue interest on trade receivables. If accounts become uncollectible, they will be written off through a charge to the allowance for doubtful accounts. The Company has not recorded an allowance for doubtful accounts as management believes all receivables are fully collectible.
Clinical Trial Accrual	Clinical Trial Accruals
	As part of the process of preparing financial statements, the Company is required to estimate its expenses resulting from its obligation under contracts with vendors and consultants and clinical site agreements in connection with conducting clinical trials. The Company’s objective is to reflect the appropriate clinical trial expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. The Company determines accrual estimates through discussion with applicable personnel and outside service providers as to the progress of trials, or the services completed. During the course of a clinical trial, the Company adjusts its rate of clinical trial expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known at that time. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low for any particular period. Through September 30, 2013, there had been no material adjustments to the Company’s prior period estimates of accrued expenses for clinical trials. The Company’s clinical trial accrual is dependent upon the timely and accurate reporting of contract research organizations and other third-party vendors.
Revenue Recognition	Revenue Recognition
	The Company’s revenue generally consists of research related revenue under federal contracts and licensing revenue related to non-refundable upfront fees, milestone payments and royalites earned under license agreements. Revenue is recognized when the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products and/or services has occurred; (3) the selling price is fixed or determinable; and (4) collectability is reasonably assured.
	For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has “stand-alone value” to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling prices of each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods and services are delivered, limited to the consideration that is not contingent upon future deliverables. When an arrangement is accounted for as a single unit of accounting, the Company determines the period over which the performance obligations will be performed and revenue recognized.

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2013
Investments All Other Investments [Abstract]
Fair Value of Financial Instruments by Balance Sheet Class	At December 31, 2012 and September 30, 2013, these financial instruments and respective fair values have been classified as follows:
		Quoted Prices			Significant		Significant		Balance at
		in Active			Other		Unobservable		December 31,
		Markets for			Observable		Inputs		2012
		Identical Assets			Inputs		(Level 3)
		(Level 1)			(Level 2)
	Assets:
	Money Market Funds	$	67,783,021		$	—	$	—		67,783,021
	Total assets at fair value:	$	67,783,021		$	—	$	—	$	67,783,021
		Quoted Prices			Significant		Significant		Balance at
		in Active			Other		Unobservable		September 30,
		Markets for			Observable		Inputs		2013
		Identical Assets			Inputs		(Level 3)
		(Level 1)			(Level 2)
	Assets:
	Money Market Funds	$	106,661,559		$	—	$	—		106,661,559
	Total assets at fair value:	$	106,661,559		$	—	$	—	$	106,661,559
	Liabilities:
	Warrant liabilities	$	—		$	—	$	821,138		821,138
		$	—		$	—	$	821,138	$	821,138
Change in the Fair Value Measurement Using Significant Unobservable Inputs (Level 3)	The change in the fair value measurement using significant unobservable inputs (Level 3) is summarized below:
	Balance at December 31, 2012	$	—
	Allocation of long-term debt proceeds to warrant (Unaudited)		461,144
	Reclassification of additional paid-in capital to warrant (Unaudited)		241,587
	Change in fair value recorded as interest income (Unaudited)		(14,355	)
	Change in fair value recorded as interest expense (Unaudited)		132,762
	Balance at September 30, 2013 (Unaudited)	$	821,138

Furniture_Fixtures_and_Equipme1

Furniture, Fixtures and Equipment (Tables)	9 Months Ended
	Sep. 30, 2013
Property Plant And Equipment [Abstract]
Summary of Furniture, Fixtures and Equipment	Furniture, fixtures and equipment consist of the following as of:
		Useful Life		December 31,		September 30,
		(years)		2012		2013
						(Unaudited)
	Computer equipment		2	$	191,889	$	215,104
	Software		2		46,594		39,952
	Furniture		5		38,792		38,792
	Leasehold improvements		3		4,809		13,680
	Total furniture, fixtures and equipment				282,084		307,528
	Less accumulated depreciation				238,867		235,169
	Furniture, fixtures and equipment, net			$	43,217	$	72,359

Accrued_Expenses_Tables

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2013
Payables And Accruals [Abstract]
Accrued Expenses	Accrued expenses are comprised of the following as of:
		December 31,		September 30,
		2012		2013
				(Unaudited)
	Accrued professional fees	$	207,362	$	242,977
	Other accrued fees		30,817		45,693
	Accrued interest		82,236		119,375
	Deferred rent		21,503		14,750
	Total accrued expenses	$	341,918	$	422,795

Share_Option_Plans_Tables

Share Option Plans (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share Option Plans	The following table summarizes the Company’s 2006 Plan and 2011 Plan activity:
			Number of			Weighted		Weighted		Aggregate
			Options			Average		Average		Intrinsic
						Exercise		Contractual		Value (1)
						Price		Term (in years)
	Outstanding—December 31, 2012			1,162,602		$	4.18
	Granted			698,473			6.73
	Exercised			—			—
	Forfeited			(54,539	)		7.62
	Expired			—			—
	Outstanding—September 30, 2013			1,806,536			5.07		7.83	$	11,622,016
	Exercisable—September 30, 2013			1,376,922			4.79		7.48	$	9,245,384
	Vested and expected to vest at September 30, 2013 (2)			1,763,647		$	5.04		7.8	$	11,384,658
	(1)	Intrinsic value is the excess of the fair value of the underlying common shares as of September 30, 2013 over the weighted-average exercise price.
	(2)	The number of stock options expected to vest takes into account an estimate of expected forfeitures.
Options Outstanding	The following table summarizes certain information about all options outstanding as of September 30, 2013:
			Options Outstanding					Options Exercisable
	Exercise Price		Number of			Weighted		Number of		Weighted
			Options			Average		Options		Average
						Remaining				Remaining
						Contractual				Contractual
						Term (in years)				Term (in years)
	$0.48—$1.71			97,688			2.94		97,688		2.94
	$1.71—$2.94			604,497			6.35		526,148		6.22
	$5.40—$7.86			1,104,351			9.07		753,086		8.94
				1,806,536					1,376,922

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]
Antidilutive Securities Excluded from Computation of Diluted Weighted Average Shares Outstanding	The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding, as they would be antidilutive:
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2012		2013		2012		2013
		(Unaudited)				(Unaudited)
	Redeemable convertible preferred shares		—		—		923,847		—
	Convertible debt		—		—		59,685		—
	Warrants outstanding		247,370		340,519		236,217		289,723
	Stock options outstanding		1,157,545		1,815,830		1,011,738		1,699,525
			1,404,915		2,156,349		2,231,487		1,989,248

Description_of_Business_Additi

Description of Business - Additional Information (Detail) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

94 Months Ended

Dec. 31, 2005

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2008

Dec. 31, 2007

Dec. 31, 2006

Sep. 30, 2013

Adjusted Earnings Before Interest Taxes Depreciation And Amortization And Other Non Cash Items [Abstract]

Net loss

($26,463)

($13,647,496)

($4,981,115)

($28,205,452)

($17,658,800)

($24,226,789)

($21,220,779)

($19,674,924)

($18,611,814)

($14,902,317)

($8,075,240)

($2,228,948)

($137,172,726)

Basis_of_Presentation_Addition

Basis of Presentation - Additional Information (Detail) (USD $)	Sep. 30, 2013
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Allowance for doubtful accounts receivable recorded	$0

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments - Fair Value of Financial Instruments by Balance Sheet Class (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]
Total assets at fair value:	$106,661,559	$67,783,021
Total liabilities at fair value:	821,138
Warrant Liabilities [Member]
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]
Total liabilities at fair value:	821,138
Money Market Funds [Member]
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]
Total assets at fair value:	106,661,559	67,783,021
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]
Total assets at fair value:	106,661,559	67,783,021
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Money Market Funds [Member]
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]
Total assets at fair value:	106,661,559	67,783,021
Significant Other Observable Inputs (Level 2) [Member]
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]
Total assets at fair value:
Total liabilities at fair value:
Significant Other Observable Inputs (Level 2) [Member] | Warrant Liabilities [Member]
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]
Total liabilities at fair value:
Significant Other Observable Inputs (Level 2) [Member] | Money Market Funds [Member]
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]
Total assets at fair value:
Significant Unobservable Inputs (Level 3) [Member]
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]
Total liabilities at fair value:	821,138
Significant Unobservable Inputs (Level 3) [Member] | Warrant Liabilities [Member]
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]
Total liabilities at fair value:	$821,138

Fair_Value_of_Financial_Instru3

Fair Value of Financial Instruments - Change in the Fair Value Measurement Using Significant Unobservable Inputs (Level 3) (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]
Balance at December 31, 2012
Allocation of long-term debt proceeds to warrant (Unaudited)	461,144
Reclassification of additional paid-in capital to warrant (Unaudited)	241,587
Change in fair value recorded as interest income (Unaudited)	-14,355
Change in fair value recorded as interest expense (Unaudited)	132,762
Balance at September 30, 2013 (Unaudited)	$821,138

Fair_Value_of_Financial_Instru4

Fair Value of Financial Instruments - Additional Information (Detail) (USD $)	3 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Transfers between levels of the fair value hierarchy	$0	$0
December 2011 Note [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Carrying value of notes	$14.50	$14.50

Significant_Agreements_and_Con1

Significant Agreements and Contracts - Additional Information (Detail) (USD $)	3 Months Ended	9 Months Ended	94 Months Ended	1 Months Ended		9 Months Ended		3 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Jul. 31, 2012	Jul. 31, 2010	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Jun. 30, 2013
				Optimer Agreement [Member]	Optimer Agreement [Member]	Optimer Agreement [Member]	The Scripps Research Institute [Member]	Biomedical Advanced Research and Development Authority [Member]	Biomedical Advanced Research and Development Authority [Member]	Toyama Chemical [Member]	Toyama Chemical [Member]
						Product			Segment	Deliverables
Collaborative Arrangements Non collaborative Arrangements And Business Acquisitions Transactions [Line Items]
Common shares issued to Optimer in exchange for license						125,646
Fair value of common shares issued to Optimer						$190,418
Milestone payment paid to Optimer				1,000,000	500,000
Aggregate amount of milestone payment						27,500,000
Number of products required to be developed through FDA approval						4
Royalty payment based on annual net sales description						The Company will also pay tiered mid-single-digit royalties based on the amount of annual net sales of its approved products.	Under the terms of the agreement, the Company must pay TSRI low single-digit percentage royalties on the net sales of the products covered by the TSRI patents for the life of the TSRI patents, a low single-digit percentage of non-royalty sublicensing revenue received with respect to countries in the nonexclusive territory and a mid-single-digit percentage of sublicensing revenue received with respect to countries in the exclusive territory, with the sublicensing revenue royalty in the exclusive territory and the sales royalties subject to certain reductions under certain circumstances
Non refundable license issue fee							350,000
Annual maintenance fees for first three years							50,000
Annual maintenance fees after three years (beginning on the fourth anniversary of the agreement)							85,000
Eligible milestone payment							1,100,000
Value of cost plus fixed fee development contract with base performance segment									17,700,000
Number of option work segments									4
Cumulative value of cost plus fixed fee development contract with base performance segment of four option work segments									58,000,000
Number of options under cost plus fixed fee arrangements									3
Number of options under cost sharing arrangement									1
Aggregate milestone payments receivable under license agreement								24-May-13
Estimated period of performance for the base performance segment ending date								23-May-15
Extended estimated period of performance for the base performance segment									23-May-18
Contracts research	1,172,268	1,404,608	1,404,608					1,200,000	1,400,000
Upfront payment received under license agreement										10,000,000
Aggregate milestone payments											60,000,000
Number of deliverables under license agreement										6
License		4,335,412	4,335,412							4,300,000
Deferred revenue										$5,700,000

Receivables_Additional_Informa

Receivables - Additional Information (Detail) (USD $)	Sep. 30, 2013
Receivables [Abstract]
Unbilled receivables	$974,778

Furniture_Fixtures_and_Equipme2

Furniture, Fixtures and Equipment - Summary of Furniture, Fixtures and Equipment (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Total furniture, fixtures and equipment	$307,528	$282,084
Less accumulated depreciation	235,169	238,867
Furniture, fixtures and equipment, net	72,359	43,217
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful Life (years)	2 years
Total furniture, fixtures and equipment	215,104	191,889
Software [Member]
Property, Plant and Equipment [Line Items]
Useful Life (years)	2 years
Total furniture, fixtures and equipment	39,952	46,594
Furniture [Member]
Property, Plant and Equipment [Line Items]
Useful Life (years)	5 years
Total furniture, fixtures and equipment	38,792	38,792
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Useful Life (years)	3 years
Total furniture, fixtures and equipment	$13,680	$4,809

Furniture_Fixtures_and_Equipme3

Furniture, Fixtures and Equipment - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended		94 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Property Plant And Equipment Useful Life And Values [Abstract]
Depreciation expense	$7,641	$5,452	$21,546	$41,880	$263,389

Accrued_Expenses_Accrued_Expen

Accrued Expenses - Accrued Expenses (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Accrued Liabilities Current [Abstract]
Accrued professional fees	$242,977	$207,362
Other accrued fees	45,693	30,817
Accrued interest	119,375	82,236
Deferred rent	14,750	21,503
Total accrued expenses	$422,795	$341,918

LongTerm_Debt_Additional_Infor

Long-Term Debt - Additional Information (Detail) (USD $)	1 Months Ended	9 Months Ended
	Dec. 31, 2011	Sep. 30, 2013	31-May-13
Debt Instrument [Line Items]
Loan and security agreement	$20,000,000		$15,000,000
Long-term debt, borrowed	10,000,000
Percentage of Long-term debt, interest of borrowing	3.25%
Long-term debt, interest of borrowing	Interest at the greater of (i) 9.55%, or (ii) the sum of 9.55% plus the prime lending rate, as published by the Wall Street Journal, minus 3.25% per annum
Extend date of additional borrowing		30-Sep-13
Amortization period of principal and interest payments		36 months
Long term debt maturity date		1-Jun-17
Long term debt maturity start date		1-Jul-14
Advances and interest payable		495,245
Line of credit facility fees payment date description		earliest to occur of (i) June 1, 2017, (ii) the date that the Company prepays all of the outstanding advances and accrued interest, or (iii) the date that all of the advances and interest become due and payable
Line of credit facility fees repayment date		1-Jun-17
Exercisable, share of common stock		39,038
Warrant expire date		20-Dec-21
Devisable amount of common stock equal to quotient		609,533
9.55% Long-Term Debt [Member]
Debt Instrument [Line Items]
Percentage of convertible notes	9.55%	9.55%
Additional borrowing		10,000,000
Advances and interest payable		400,000
Line of credit facility fees payment date description		earliest to occur of (i) December 1, 2015, (ii) the date that the Company prepays all of the outstanding advances and accrued interest, or (iii) the date that all of the advances and interest become due and payable
Line of credit facility fees repayment date		1-Dec-15
Warrants issued, per share		$10.25
Term Loan A [Member]
Debt Instrument [Line Items]
Long-term debt, borrowed			$5,238,327
First Hercules Warrant [Member]
Debt Instrument [Line Items]
Exercise price of the warrant		6.11
Second Hercules Warrant [Member]
Debt Instrument [Line Items]
Exercise price of the warrant		6.11
Warrant expire date		31-May-23

Shareholders_Equity_Deficit_Ad

Shareholders' Equity (Deficit) - Additional Information (Detail) (USD $)	1 Months Ended			9 Months Ended
In Millions, except Share data, unless otherwise specified	Jun. 30, 2013	Oct. 31, 2012	Feb. 29, 2012	Sep. 30, 2013	Dec. 31, 2012
Equity [Abstract]
Issuance of common stock upon initial public offering, shares			9,660,000
Price for initial public offering			$6
Net proceeds to the company	$54.20		$53.20
Underwriting discounts	3.5		3.2
Offering costs	0.2		1.6
Company's outstanding preferred shares, accrued yield				13.7
Converted shares of common stock				9,958,502
Converted shares of common stock				876,621
Issuance of common stock to certain institutional accredited investors		3,864,461
Common stock per share		$6.50
Raising from issuance of private placement		25.1
Private placement sales agency fees and offering cost		$1.70
Shares issued of common stock	8,273,938			33,186,656	24,903,774
Exercise price of common stock	$7

Share_Option_Plans_Additional_

Share Option Plans - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended		94 Months Ended				1 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Dec. 31, 2012	Oct. 31, 2011	Sep. 30, 2013	Jan. 31, 2013	31-May-13
								2006 Plan [Member]	2011 Plan [Member]	2011 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options for shares issued and outstanding	1,806,536		1,806,536		1,806,536	1,162,602		702,185
Maximum number of shares authorized for future issuances							1,526,316
Share-based payment award, number of additional shares authorized									105,263
Increase of shares reserved										1,500,000
Options shares available under the 2011 Plan	2,024,728		2,024,728		2,024,728
Share-based compensation expense	$861,392	$518,572	$2,480,137	$1,189,182	$5,172,707
Unrecognized compensation cost	$1,741,000		$1,741,000		$1,741,000
Expected weighted average recognition period, Unvested shares			1 year 9 months 18 days

Share_Option_Plans_Share_Optio

Share Option Plans - Share Option Plans (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Options, Outstanding - December 31, 2012	1,162,602
Number of Options, Granted	698,473
Number of Options, Exercised
Number of Options, Forfeited	-54,539
Number of Options, Expired
Number of Options, Outstanding - September 30, 2013	1,806,536
Number of Options, Exercisable - September 30, 2013	1,376,922
Number of Options, Vested and expected to vest at September 30, 2013	1,763,647
Weighted Average Exercise Price, Outstanding - December 31, 2012	$4.18
Weighted Average Exercise Price, Granted	$6.73
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Forfeited	$7.62
Weighted Average Exercise Price, Expired
Weighted Average Exercise Price, Outstanding - September 30, 2013	$5.07
Weighted Average Exercise Price, Exercisable - September 30, 2013	$4.79
Weighted Average Exercise Price, Vested and expected to vest at September 30, 2013	$5.04
Weighted Average Contractual Term (in years), Outstanding - September 30, 2013	7 years 9 months 29 days
Weighted Average Contractual Term (in years), Exercisable - September 30, 2103	7 years 5 months 23 days
Weighted Average Contractual Term (in years), Vested and expected to vest at September 30, 2013	7 years 9 months 18 days
Aggregate Intrinsic Value, Outstanding - September 30, 2013	$11,622,016
Aggregate Intrinsic Value, Exercisable - September 30, 2013	9,245,384
Aggregate Intrinsic Value, Vested and expected to vest at September 30, 2013	$11,384,658

Share_Option_Plans_Options_Out

Share Option Plans - Options Outstanding (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	1,806,536	1,162,602
Weighted Average Remaining Contractual Term (in years), Outstanding	7 years 9 months 29 days
Number of Options, Exercisable	1,376,922
Weighted Average Remaining Contractual Term (in years), Exercisable	7 years 5 months 23 days
Exercise Price $0.48 - $1.71 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range lower range limit	0.48
Exercise price range upper range limit	1.71
Number of Options Outstanding	97,688
Weighted Average Remaining Contractual Term (in years), Outstanding	2 years 11 months 9 days
Number of Options, Exercisable	97,688
Weighted Average Remaining Contractual Term (in years), Exercisable	2 years 11 months 9 days
Exercise Price $ 1.71- $2.94 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range lower range limit	1.71
Exercise price range upper range limit	2.94
Number of Options Outstanding	604,497
Weighted Average Remaining Contractual Term (in years), Outstanding	6 years 4 months 6 days
Number of Options, Exercisable	526,148
Weighted Average Remaining Contractual Term (in years), Exercisable	6 years 2 months 19 days
Exercise Price $5.40 - $7.86 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range lower range limit	5.4
Exercise price range upper range limit	7.86
Number of Options Outstanding	1,104,351
Weighted Average Remaining Contractual Term (in years), Outstanding	9 years 26 days
Number of Options, Exercisable	753,086
Weighted Average Remaining Contractual Term (in years), Exercisable	8 years 11 months 9 days

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]
Effective tax rate	0.00%
Income tax expense	$0

Net_Loss_Per_Share_Antidilutiv

Net Loss Per Share - Antidilutive Securities Excluded from Computation of Diluted Weighted Average Shares Outstanding (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted average shares outstanding	2,156,349	1,404,915	1,989,248	2,231,487
Series A Preferred Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted average shares outstanding				923,847
Convertible Debt [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted average shares outstanding				59,685
Warrant Liabilities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted average shares outstanding	340,519	247,370	289,723	236,217
Stock Options Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted average shares outstanding	1,815,830	1,157,545	1,699,525	1,011,738